Spero Therapeutics, Inc. (NASDAQ:SPRO) Major Shareholder Aquilo Capital Management, Llc Acquires 39,727 Shares

Spero Therapeutics, Inc. (NASDAQ:SPROGet Rating) major shareholder Aquilo Capital Management, Llc bought 39,727 shares of the firm’s stock in a transaction on Tuesday, April 26th. The stock was acquired at an average cost of $5.24 per share, with a total value of $208,169.48. Following the completion of the transaction, the insider now directly owns 5,321,231 shares of the company’s stock, valued at $27,883,250.44. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Aquilo Capital Management, Llc also recently made the following trade(s):

  • On Wednesday, March 30th, Aquilo Capital Management, Llc bought 50,000 shares of Spero Therapeutics stock. The stock was acquired at an average cost of $8.79 per share, with a total value of $439,500.00.
  • On Monday, January 31st, Aquilo Capital Management, Llc bought 125,000 shares of Spero Therapeutics stock. The stock was acquired at an average cost of $11.59 per share, with a total value of $1,448,750.00.

Shares of NASDAQ:SPRO opened at $5.01 on Friday. The company has a market capitalization of $164.11 million, a price-to-earnings ratio of -1.73 and a beta of 1.65. The firm’s 50 day simple moving average is $7.69 and its 200 day simple moving average is $11.90. Spero Therapeutics, Inc. has a fifty-two week low of $4.65 and a fifty-two week high of $19.87.

Spero Therapeutics (NASDAQ:SPROGet Rating) last released its earnings results on Thursday, March 31st. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.09). Spero Therapeutics had a negative net margin of 491.65% and a negative return on equity of 87.72%. During the same quarter in the prior year, the firm earned ($0.68) earnings per share. On average, equities analysts anticipate that Spero Therapeutics, Inc. will post -3.73 earnings per share for the current year.

A number of analysts have recently weighed in on the stock. HC Wainwright reduced their price objective on shares of Spero Therapeutics from $43.00 to $37.00 and set a “buy” rating for the company in a research note on Monday, April 18th. Zacks Investment Research cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 5th.

Hedge funds and other institutional investors have recently modified their holdings of the business. Granahan Investment Management Inc. MA raised its stake in Spero Therapeutics by 67.0% during the third quarter. Granahan Investment Management Inc. MA now owns 555,614 shares of the company’s stock worth $10,229,000 after acquiring an additional 222,975 shares in the last quarter. Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Spero Therapeutics during the fourth quarter worth about $66,000. Royal Bank of Canada grew its holdings in shares of Spero Therapeutics by 8,249.7% during the third quarter. Royal Bank of Canada now owns 180,102 shares of the company’s stock worth $3,316,000 after purchasing an additional 177,945 shares during the last quarter. Barclays PLC grew its holdings in shares of Spero Therapeutics by 79.1% during the third quarter. Barclays PLC now owns 9,965 shares of the company’s stock worth $183,000 after purchasing an additional 4,401 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in shares of Spero Therapeutics by 10.6% during the third quarter. Janney Montgomery Scott LLC now owns 26,000 shares of the company’s stock worth $479,000 after purchasing an additional 2,500 shares during the last quarter. 59.17% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile (Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

See Also

Insider Buying and Selling by Quarter for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.